• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RHY
Click for more information
8.57% 6.4¢

RHYTHM BIOSCIENCES LIMITED - News & Media

Market Cap $15.41M  ! watchlist Created with Sketch. Add to my watchlist

Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is... Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. It is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No News & Media currently available.

(20min delay)
Last
6.4¢ 		Change
-0.006(8.57%) 		Mkt cap ! $15.41M
Open High Low Value Volume
7.1¢ 7.4¢ 6.2¢ $26.95K 399.8K

Buyers (Bids)

No. Vol. Price($)
1 30000 6.4¢
 

Sellers (Offers)

Price($) Vol. No.
7.6¢ 12800 1
View Market Depth
Last trade - 11.54am 30/09/2024 (20 minute delay) ?
Last
6.2¢ 		  Change
-0.006 ( 15.1 %)
Open High Low Volume
7.3¢ 7.3¢ 6.2¢ 177200
Last updated 10.54am 30/09/2024 ?
RHY (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Zenith's sale of Develin Creek delivers $975K cash, with shares up 13% Zenith Minerals Ltd has completed its sale of Develin Creek copper-zinc project in Queensland to QMines Ltd
The iron ore comeback: Can it last? The Chinese need our iron ore and we could do with the cash if we are sensible enough to put the stuff on a boat and sell it to them.
Hastings progressing Yangibana to production with lower costs Hastings Technology Metals Ltd has released its annual report to shareholders, saying that it has reduced capital costs by $56 million
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.